Immunoexpression of claudins 4 and 7 among invasive breast carcinoma subtypes: A large diagnostic study using tissue microarray

Imagem de Miniatura
Arquivos
art_LOGULLO_Immunoexpression_of_claudins_4_and_7_among_invasive_2018.PDF (611.04 KB)
Citações na Scopus
Tipo de produção
article
Data de publicação
2018
DOI
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
SPANDIDOS PUBL LTD
Autores
LOGULLO, Angela Flavia
NONOGAKI, Suely
ROCHA, Rafael Malagoli
SOARES, Fernando Augusto
Citação
MOLECULAR AND CLINICAL ONCOLOGY, v.9, n.4, p.377-388, 2018
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Molecular phenotyping and tissue microarray (TMA) studies have identified distinct invasive breast carcinoma subtypes: Luminal A, luminal B, enriched with overexpressed human epidermal growth factor receptor 2 (HER-2) and triple-negative, i.e., negative for HER-2, as well as for estrogen and progesterone receptor (ER and PR, respectively) expression. These subtypes are useful in clinical management, since they bear distinct prognoses and predictive responses to targeted therapy. However, although molecular profiling provides important prognostic indicators, breast cancer risk stratification remains a challenge in triple-negative cases. What is referred to as claudin-low subtype was identified as a triple-negative subset that is associated with more aggressive tumor behavior and worse prognosis. However, the immunohistochemical expression of claudins has not yet been standardized. Our objective was to verify whether the immunoexpression of claudins 4 and 7 (the main claudins specifically expressed in human breast tissue) in TMA is associated with survival and prognosis in luminal A, HER-2 and triple-negative molecular subtypes. In this diagnostic study, we investigated ER/PR receptor status, HER-2, claudin 4 and 7 expression and stem cell CD44/24 profiles, and verified the association with prognosis and survival outcomes in 803 invasive breast carcinoma cases arranged in four TMAs. Among these, 503 (62.6%) were positive for claudin 4 and 369 (46.0%) for claudin 7. Claudin 4 exhibited the lowest expression in luminal A and triple-negative subtypes, and the highest frequency of expression in HER-2-enriched subtypes, whereas claudin 7 staining was not associated with any subtype. The stem cell phenotype was not associated with subgroups or claudins 4 and 7. Claudin immunoexpression profile was not able to distinguish between patients with better or worse prognosis, and it was not correlated to triple-negative cases. Therefore, it may be concluded that the immunoexpression of claudins 4 and 7, individually or within the usual immunohistochemical context (ER, PR and HER-2), does not provide additional prognostic information on breast cancer subtypes.
Palavras-chave
claudin 4, claudin 7, breast carcinoma, immunohistochemistry, tissue microarray analysis
URI
https://observatorio.fm.usp.br/handle/OPI/30826
Referências
  1. Abd El-Rehim DM, 2005, INT J CANCER, V116, P340, DOI 10.1002/ijc.21004
  2. Achari C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130300
  3. Allred DC, 1998, MODERN PATHOL, V11, P155
  4. Bernardi MA, 2012, ONCOL REP, V27, P28, DOI 10.3892/or.2011.1477
  5. Blanchard AA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163387
  6. Blanchard AA, 2009, VIRCHOWS ARCH, V454, P647, DOI 10.1007/s00428-009-0770-6
  7. Carey LA, 2006, JAMA-J AM MED ASSOC, V295, P2492, DOI 10.1001/jama.295.21.2492
  8. Cheang MCU, 2009, JNCI-J NATL CANCER I, V101, P736, DOI 10.1093/jnci/djp082
  9. Dias K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0168669
  10. Farahani E, 2014, CARCINOGENESIS, V35, P747, DOI 10.1093/carcin/bgu045
  11. Gerhard R, 2012, BREAST, V21, P354, DOI 10.1016/j.breast.2012.03.001
  12. Giuliano AE, 2017, CA-CANCER J CLIN, V67, P291, DOI 10.3322/caac.21393
  13. Hagemann IS, 2016, ARCH PATHOL LAB MED, V140, P815, DOI 10.5858/arpa.2016-0051-RA
  14. Hennessy BT, 2009, CANCER RES, V69, P4116, DOI 10.1158/0008-5472.CAN-08-3441
  15. Iravani O, 2016, J CLIN PATHOL, V69, P878, DOI 10.1136/jclinpath-2015-203265
  16. Katayama A, 2017, PATHOL INT, V67, P404, DOI 10.1111/pin.12560
  17. Khan N, 2015, MEDIAT INFLAMM, DOI 10.1155/2015/219843
  18. Kolokytha P, 2014, APPL IMMUNOHISTO M M, V22, P125, DOI 10.1097/PAI.0b013e31828d9d62
  19. Kominsky SL, 2003, ONCOGENE, V22, P2021, DOI 10.1038/sj.onc.1206199
  20. Kulka J, 2009, PATHOL ONCOL RES, V15, P59, DOI 10.1007/s12253-008-9089-x
  21. Kwon MJ, 2013, INT J MOL SCI, V14, P18148, DOI 10.3390/ijms140918148
  22. Lanigan F, 2009, INT J CANCER, V124, P2088, DOI 10.1002/ijc.24159
  23. Lehmann Ulrich, 2012, Methods Mol Biol, V878, P229, DOI 10.1007/978-1-61779-854-2_15
  24. Lin XJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067496
  25. Lu SL, 2013, MODERN PATHOL, V26, P485, DOI 10.1038/modpathol.2012.187
  26. Mangone FRR, 2005, INT J EXP PATHOL, V86, P205, DOI 10.1111/j.0959-9673.2005.00423.x
  27. Marchio C, 2017, CURR DRUG TARGETS, V18, P4, DOI 10.2174/1389450116666150203121218
  28. Mardekian SK, 2016, HUM PATHOL, V49, P114, DOI 10.1016/j.humpath.2015.11.003
  29. Matsumoto A, 2016, JPN J CLIN ONCOL, V46, P99, DOI 10.1093/jjco/hyv153
  30. Morohashi S, 2007, INT J MOL MED, V20, P139
  31. Myal Y, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/956897
  32. Park D, 2007, APMIS, V115, P52, DOI 10.1111/j.1600-0463.2007.apm_524.x
  33. Prat A, 2013, BREAST CANCER RES TR, V142, P237, DOI 10.1007/s10549-013-2743-3
  34. Prat A, 2011, MOL ONCOL, V5, P5, DOI 10.1016/j.molonc.2010.11.003
  35. Prat A, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2635
  36. Rakha EA, 2008, J CLIN ONCOL, V26, P3153, DOI 10.1200/JCO.2007.15.5986
  37. Sabatier R, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-228
  38. Sauer T, 2005, CYTOPATHOLOGY, V16, P193, DOI 10.1111/j.1365-2303.2005.00257.x
  39. Singh AB, 2015, SEMIN CELL DEV BIOL, V42, P58, DOI 10.1016/j.semcdb.2015.05.001
  40. Soini Y, 2005, HISTOPATHOLOGY, V46, P551, DOI 10.1111/j.1365-2559.2005.02127.x
  41. Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
  42. Szasz AM, 2011, CANCER SCI, V102, P2248, DOI 10.1111/j.1349-7006.2011.02085.x
  43. Tan WG, 2016, ONCOTARGET, V7, P10373, DOI 10.18632/oncotarget.7219
  44. Tang P, 2016, ARCH PATHOL LAB MED, V140, P806, DOI 10.5858/arpa.2015-0133-RA
  45. Tokes AM, 2005, BREAST CANCER RES, V7, pR296, DOI 10.1186/bcr983
  46. Wolff AC, 2014, ARCH PATHOL LAB MED, V138, P241, DOI 10.5858/arpa.2013-0953-SA
  47. Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI 10.1200/JCO.2013.50.9984

Coleções
Artigos e Materiais de Revistas Científicas - FM/MDR
Artigos e Materiais de Revistas Científicas - LIM/24